CDR-Engineered Anti-CD79B Antibody for Accurate Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD79B antibodies suffer from false-positive and false-negative results due to aberrant expression or cross-reactivity in non-B cell-derived tumors and low expression levels, compromising diagnostic accuracy in immunological assays.
Innovation Solution
Development of an anti-CD79B protein monoclonal antibody with specific CDR and FR sequences (SEQ ID NOs:1-16) for enhanced specificity and sensitivity, suitable for immunological detection methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing CD79B antibodies are used for immunological detection, then detection can be performed, but false-positive and false-negative results occur due to aberrant expression or cross-reactivity in non-B cell-derived tumors and low expression levels
Solution Approach 1:
The patent applies local quality by designing the antibody to specifically recognize and bind to the CD79B protein at its precise epitope location. The monoclonal antibody is engineered with specific complementarity-determining regions (CDRs) that target the unique structural features of CD79B, ensuring high-specificity binding only to the intended antigen while avoiding cross-reactivity with other proteins or aberrant expressions in non-B cell-derived tumors.
Solution Approach 2:
The patent employs parameter changes by optimizing the antibody's binding affinity and specificity parameters. Through systematic modification of the antibody's amino acid sequence in the CDR regions, the invention achieves enhanced binding strength to CD79B while maintaining selectivity. This allows the antibody to detect even low expression levels of CD79B without producing false-positive or false-negative results.
2Ease of operation
If existing CD79B antibodies are used, then detection is possible, but aberrant expression or cross-reactivity in non-B cell-derived tumors leads to false-positive results
Solution Approach 1:
The patent applies local quality by designing the antibody to specifically recognize and bind to the CD79B protein at its precise epitope location. The monoclonal antibody is engineered with specific complementarity-determining regions (CDRs) that target the unique structural features of CD79B, ensuring high-specificity binding only to the intended antigen while avoiding cross-reactivity with other proteins or aberrant expressions in non-B cell-derived tumors.
3Ease of operation
If existing CD79B antibodies are used, then detection can be performed, but weak staining or undetectable signals occur in lesions or tumor cells with low CD79B expression, resulting in false-negative outcomes
Solution Approach 1:
The patent employs parameter changes by optimizing the antibody's binding affinity and specificity parameters. Through systematic modification of the antibody's amino acid sequence in the CDR regions, the invention achieves enhanced binding strength to CD79B while maintaining selectivity. This allows the antibody to detect even low expression levels of CD79B without producing false-positive or false-negative results.
Data Source
AI summary
An anti-CD79B protein monoclonal antibody and related products and uses thereof are disclosed. The anti-CD79B protein monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain includes a heavy chain variable region, and the light chain includes a light chain variable region. The heavy chain variable region includes complementary-determining regions CDR1, CDR2, and CDR3 with amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively. The light chain variable region comprises complementary-determining regions CDR1, CDR2, and CDR3 with amino acid sequences as shown in SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, respectively. The anti-CD79B protein monoclonal antibody exhibits high specificity and sensitivity, enabling specific recognition of cells expressing CD79B protein. It is suitable for immunological detection, and effectively prevents false-positive and false-negative results in immunological assays, thereby further improving the accuracy of detection and diagnostic outcomes.